Hypertrophic cardiomyopathy considerations for the managed care pharmacist

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Hypertrophic cardiomyopathy (HCM) is an autosomal dominant genetic heart disease characterized by left ventricular hypertrophy.
• While many patients have a genetic etiology, some do not, presenting a variable clinical course.
• Younger diagnosis and sarcomere variants increase lifelong risks for stroke, heart failure, arrhythmias, and mortality.

Purpose of the Study:

• To review current management strategies for hypertrophic cardiomyopathy (HCM).
• To evaluate the potential impact of emerging cardiac myosin inhibitors on HCM treatment.
• To inform managed care pharmacists about the assessment of new HCM therapies.

Main Methods:

• Review of current literature on hypertrophic cardiomyopathy (HCM) diagnosis, risk stratification, and treatment.
• Analysis of clinical trial data for cardiac myosin inhibitors.
• Consideration of economic and quality-of-life impacts of HCM management.

Main Results:

• Current HCM interventions improve survival but incur significant costs and morbidities.
• Cardiac myosin inhibitors demonstrate promise in clinical trials for targeting the underlying pathology of HCM.
• Shared decision-making and multidisciplinary care improve patient outcomes.

Conclusions:

• Existing HCM treatments manage symptoms but not the root cause.
• Cardiac myosin inhibitors represent a potential disease-modifying therapy for HCM.
• Further long-term data on safety, efficacy, and cost-effectiveness are needed for FDA-approved cardiac myosin inhibitors.